• Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Exosomes
  • iPSC
  • Partnering
    • Existing Partnerships & Collaborations
  • News
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • General Meetings
    • Financial Calendar
    • Email alerts
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us
ReNeuron logo
ReNeuron logo
  • Home
  • About Us
    • About ReNeuron
    • Board of Directors
    • Senior Management
    • Advisory Board
    • Working at ReNeuron
    • Patents
  • Exosomes
  • iPSC
  • Partnering
    • Existing Partnerships & Collaborations
  • News
  • Investors
    • Investor Centre
    • Corporate Governance
    • Share Price Information
    • Major Shareholdings
    • Advisors
    • Analyst Research
    • Financial Reports
    • General Meetings
    • Financial Calendar
    • Email alerts
    • RNS Notifications
    • Documents and Circulars
    • AIM Rule 26
    • Declarations
  • Contact
    • Contact Us

Presentations: Observational study in stroke

CFO Michael Hunt Presents at Shares Magazine Investor Evening – 27th October 2016
CEO Presents at the 6th Annual Cell & Gene Partnering Forum on the Mesa 2016
CEO Presents at Cell & Gene Therapy Investor Day March 2016

Section: News

  • News
    • News Archive
  • Events

Filter by:

  • Corporate
  • Product
    • Induced pluripotent stem cell (iPSC) Platform
    • CTX cells for Stroke Disability
    • CTX cells for Critical Limb Ischaemia
    • hRPCs for Retinitis Pigmentosa
    • CTX-derived Exosomes
  • Trial
    • Phase III clinical trial in stroke disability (PISCES-III)
    • Phase I clinical trial in stroke disability (PISCES)
    • Phase II clinical trial in stroke disability (PISCES-II)
    • Observational study in stroke
    • Phase I trial in critical limb ischaemia
    • Phase I/II clinical trial in retinitis pigmentosa

© ReNeuron Group plc 2023 All rights reserved

Website design by Carr Kamasa Design

  • Privacy Notice
  • Disclaimer